CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.07.17	Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering (Businesswire)
10.07.17	Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million (Businesswire)
27.06.17	First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital (Businesswire)
23.06.17	Calyxt Files Registration Statement for Proposed Initial Public Offering (Businesswire)
23.01.17	Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
22.11.16	Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016 (Businesswire)
21.11.16	Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY (Businesswire)
15.11.16	Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123 (Businesswire)
07.11.16	Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting (Businesswire)
31.10.16	Cellectis Hosts World’s First Gene Edited Dinner in NYC (Businesswire)
04.10.16	Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014 (Businesswire)
27.09.16	Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare (Businesswire)
08.09.16	Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results (Businesswire)
27.06.16	MIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year (Businesswire)
27.06.16	Cellectis Named 2016 Technology Pioneer by the World Economic Forum (Businesswire)
20.06.16	Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) (Businesswire)
19.05.16	Cellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016 (Businesswire)
11.05.16	Cellectis Reports First Quarter 2016 Financial Results (Businesswire)
02.05.16	Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
21.03.16	Cellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc. (Businesswire)
16.03.16	Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies (Businesswire)
08.03.16	Cellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016 (Businesswire)
02.03.16	Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility (Businesswire)
19.01.16	Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies (Businesswire)
11.01.16	Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
07.01.16	Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team (Businesswire)
23.12.15	Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies (Businesswire)
21.12.15	Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016 (Businesswire)
03.12.15	Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier (Businesswire)
30.11.15	Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
19.11.15	Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies (Businesswire)
16.11.15	Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results (Businesswire)
05.11.15	Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Product Candidates during the Upcoming ASH Annual Meeting (Businesswire)
05.11.15	Cellectis: UCART19: First in Man Proof of Concept to Be Presented at 2015 ASH Annual Meeting (Businesswire)
28.10.15	Successful GMP Production Process for UCART19 (Businesswire)
09.09.15	Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
08.09.15	Cellectis Reports Second Quarter and First Half Year 2015 Financial Results (Businesswire)
03.09.15	MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy (Businesswire)
26.08.15	Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences (Businesswire)
16.07.15	Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies (Businesswire)
08.07.15	Cellectis Reaches Milestone in Servier Collaboration (Businesswire)
10.06.15	Cellectis Announces Promising Study on Next Generation Engineered Allogeneic CAR T-cells (Businesswire)
09.06.15	S&W Seed Company and Calyxt, Inc. Announce Alfalfa Seed Collaboration (Businesswire)
09.06.15	Cellectis Reports First Quarter 2015 Financial Results (Businesswire)
05.06.15	Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting (Businesswire)
02.06.15	Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia (Businesswire)
20.05.15	Cellectis SA Combined General Shareholders’ Meeting of May 18, 2015 (Businesswire)
08.05.15	Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
05.05.15	Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary (Businesswire)
16.04.15	Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	129.40	0.70 %	K V
UBS Group	26.83	0.45 %	K V
Zurich Insur Gr	535.00	0.38 %	K V
Swiss Life Hldg	690.40	0.29 %	K V
CieFinRichemont	135.05	0.19 %	K V
Lonza Grp	528.60	-0.45 %	K V
Alcon	75.62	-0.53 %	K V
Kuehne+Nagel Int	201.00	-0.74 %	K V
Geberit	509.80	-0.86 %	K V
Sika	211.10	-0.98 %	K V

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten